Gilead Sciences

This early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safet…

This phase 2 study tests whether an oral antiviral pill called obeldesivir can safely shorten RSV symptoms in adults who are not hospitalized but are at higher risk for severe disease (e.g., those aged 60+ or with chronic lung conditions). Participants take the pill or a placebo,…

This study tested an experimental drug called GS-0272 in adults with rheumatoid arthritis to see if it is safe and how the body processes it. The trial was stopped early, so results are limited. About 55 people were planned to take part, receiving either the drug or a placebo.

This study tested whether a once-weekly oral combination of two experimental drugs (lepetegravir and lenacapavir pacfosacil) could control HIV as well as the standard daily pill Biktarvy. It enrolled 73 people newly diagnosed with HIV-1 who had never taken HIV medication. The stu…

This study tested an experimental oral drug called edecesertib (GS-5718) in 20 people with cutaneous lupus erythematosus, a condition where lupus affects the skin. The goal was to see if the drug could reduce skin disease activity and improve symptoms. However, the trial was term…

This study tested a drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early, so results are limited.

This study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was terminated earl…

This was a small, early-phase study testing an experimental HIV drug called GS-1219 in just 4 people living with HIV-1. The goal was to check the drug's safety and how well it fights the virus. The study was terminated early, so results are very limited.

This study tested an oral antiviral drug called obeldesivir in children from birth to under 5 years old who had RSV infection. The goal was to see if the drug is safe and helps reduce symptoms faster. However, the trial was stopped early and only enrolled 4 participants, so the r…